The current economic burden of cirrhosis.

Authors:
Address: Dr. Neff is Chief of Hepatology at Tampa General Medical Group in Tampa, Florida. Dr. Duncan is affiliated with Highline Gastroenterology in Seattle, Washington. Dr. Schiff is a Professor of Medicine and Director of the Schiff Liver Institute and the Center for Liver Diseases at the University of Miami's Miller School of Medicine in Miami, Florida.
Journal:

Publication:
Free Text: The current economic burden of cirrhosis.

abstract

cirrhosis is a worldwide problem that is associated with a substantial economic burden. Hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, and alcoholic liver disease are The main causes of cirrhosis, but cost-effective preventive strategies are only available for HBV infection. Treatment algorithms for HBV infection and HCV infection are numerous and may be economically advantageous, depending on the regimen utilized; however, effective treatment for alcoholic liver disease is lacking, with abstinence from alcohol consumption continuing to be the main treatment strategy. In addition, liver transplantation (the only cure for cirrhosis) continues to consume substantial economic resources despite a recent reduction in overall cost. More sensitive predictors of post-liver transplantation disability could reduce this cost by allowing interventions that would promote productivity and increase health-related quality of life after liver transplantation. This paper highlights recent publications that evaluate the cost-effectiveness of strategies that prevent or treat the main causes of cirrhosis as well as publications that assess the impact of quality of life on the overall cost burden of the disease.

Related Articles
Review Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Health Technol Assess. 2007
Review Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein K. Health Technol Assess. 2007 Sep; 11(34):1-206.
Review Advances in the treatment of hepatitis C.
Adv Intern Med. 2000
Review Advances in the treatment of hepatitis C.
Lawrence SP. Adv Intern Med. 2000; 45:65-105.
Review Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Health Technol Assess. 2006
Review Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A. Health Technol Assess. 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183.
Review Hepatitis viruses and liver transplantation.
J Gastroenterol Hepatol. 1997
Review Hepatitis viruses and liver transplantation.
Samuel D, Feray C, Bismuth H. J Gastroenterol Hepatol. 1997 Oct; 12(9-10):S335-41.
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
J Manag Care Pharm. 2008
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
Yuan Y, Iloeje UH, Hay J, Saab S. J Manag Care Pharm. 2008 Jan-Feb; 14(1):21-33.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.